Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: Diagnosis, monitoring, prevention, and treatment

Seminars in Hematology

Volumn 49, Issue 1, 2012, Pages 15-24

  Bacigalupo, Andrea ^a   Chien, Jason ^b   Barisione, Giovanni ^a   Pavletic, Steven ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALEMTUZUMAB; ATG F; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BORTEZOMIB; BRONCHODILATING AGENT; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FLUTICASONE; FORMOTEROL; HYDROXYCHLOROQUINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; SALBUTAMOL; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASTHMA; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CARDIOVASCULAR DISEASE; CHEST WALL OSCILLATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; EDEMA; EXPIRATORY FLOW RATE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERLIPIDEMIA; INFECTION; KIDNEY DISEASE; LONG TERM SURVIVAL; LUNG FUNCTION; MICROANGIOPATHY; MUSCLE CRAMP; NEUROPATHY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESIDUAL VOLUME; RETINOPATHY; SMALL AIRWAY DISEASE; SOMNOLENCE; SPIROMETRY; T CELL DEPLETION; TACHYCARDIA; TOTAL LUNG CAPACITY; UNSPECIFIED SIDE EFFECT;

BRONCHIOLITIS OBLITERANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855369111     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.10.005     Document Type: Article

References (53)

1. Chien J.W., Duncan S., Williams K.M., Pavletic S.Z. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:S106-S114.
2. Santo Tomas L.H., Loberiza F.R., Klein J.P., et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005, 128:153-161.
3. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
4. Au B.K., Au M.A., Chien J.W. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1072-1078.
5. Clark J.G., Crawford S.W., Madtes D.K., Sullivan K.M. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989, 111:368-376.
6. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
7. Barisione G., Bacigalupo A., Crimi E., Brusasco V. Acute bronchodilator responsiveness in bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation. Chest 2011, 139:633-639.
8. Gunn M.L., Godwin J.D., Kanne J.P., Flowers M.E., Chien J.W. High-resolution CT findings of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. J Thorac Imaging 2008, 23:244-250.
9. Yokoi T., Hirabayashi N., Ito M., et al. Broncho-bronchiolitis obliterans as a complication of bone marrow transplantation: a clinicopathological study of eight autopsy cases. Virchows Arch 1997, 431:275-282.
10. Weibel E.R. Design of airways and blood vessels considered as branching trees. The lung: scientific foundations 1997, 1061-1071. Lippincott-Raven, Philadelphia. R.G. Crystal, J.B. West (Eds.).
11. Yanai M., Sekizawa K., Ohrui T., Sasaki H., Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992, 72:1016-1023.
12. Mead J. The lung's "quiet zone". N Engl J Med 1970, 282:1318-1319.
13. Brown R., Woolcock A.J., Vincent N.J., Macklem P.T. Physiological effects of experimental airway obstruction with beads. J Appl Physiol 1969, 27:328-335.
14. Wood L.D., Engel L.A., Griffin P., Despas P., Macklem P.T. Effect of gas physical properties and flow on lower pulmonary resistance. J Appl Physiol 1976, 41:234-244.
15. Macklem P.T., Proctor D.F., Hogg J.C. The stability of peripheral airways. Respir Physiol 1970, 8:191-203.
16. Hughes J.M.B., Rosenzweig D.Y., Kivitz P.B. Site of airway closure in excised dog lungs: histologic demonstration. J Appl Physiol 1970, 29:340-344.
17. Barisione G., Bacigalupo A., Crimi E., Van Lint M.T., Lamparelli T., Brusasco V. Lung volumes and airway responsiveness following haematopoietic stem cell transplantation. Eur Respir J 2008, 32:1576-1582.
18. Chacon R.A., Corris P.A., Dark J.H., Gibson G.J. Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 2000, 19:263-269.
19. Estenne M., Van Muylem A., Knoop C., Antoine M. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution. Am J Respir Crit Care Med 2000, 162:1047-1051.
20. Verbanck S., Schuermans D., Van Muylem A., Paiva M., Noppen M., Vincken W. Ventilation distribution during histamine provocation. J Appl Physiol 1997, 83:1907-1916.
21. Peslin R., Fredberg J.J. Oscillation mechanics of the respiratory system. Handbook of physiology. Section 3: The respiratory system 1986, 145-177. American Physiological Society, Bethesda, MD. P.T. Macklem (Ed.).
22. Lutchen K.R., Greenstein J.L., Suki B. How inhomogeneities and airway walls affect frequency dependence and separation of airway and tissue properties. J Appl Physiol 1996, 80:1696-1707.
23. Lee S.J., Vogelsang G., Gilman A., Weisdorf D.J., et al. A survey of diagnosis, management and grading of Chronic GVHD. Biol Blood Marrow Transplant 2002, 8:32-39.
24. Goerner M., Gooley T., Flowers M.E., et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002, 8:47-56.
25. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002, 99:1971-1977.
26. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
27. Finke J., Bertz H., Schmoor C., et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000, 111:303-313.
28. Remberger M., Storer B., Ringden O., Anasetti C. Association between pre-transplant Thymoglobuline and reduced non relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002, 29:391-397.
29. Kroger N., Zabelina T., Kruger W., et al. In vivo T-cell depletion with re-transplant anti-thymocyte globulin reduces graft vs host disease, without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002, 29:683-689.
30. Zander A.R., Kroger N., Schleuning M., et al. ATG as part of the conditioning regimen reduces transplant related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic meyloid leukemia. Bone Marrow Transplant 2003, 32:355-361.
31. Bacigalupo A., Lamparelli T., Gualandi F., et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002, 8:656-661.
32. Bacigalupo A. Antilymphocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2004, 1:7.
33. Weiden P.L., Doney K., Storb R., Thomas E.D. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979, 27:227.
34. Ramsay N.K.C., Kersey J.H., Robinson L.L., et al. A randomized study of the prevention of acute graft versus host disease. N Engl J Med 1982, 306:392-397.
35. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
36. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
37. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
38. Socié G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
39. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005, 106:3308-3313.
40. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Response Criteria Working Group. Biol Blood Marrow Transplant 2006, 12:252-266.
41. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
42. Hildebrandt G.C., Fazekas T., Lawitschka A., et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011, 46:1283-1295.
43. Martin P.J., Pavletic S.Z. Biology and management of chronic graft-versus-host disease. Cancer Treat Res 2009, 144:277-298.
44. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12:375-396.
45. Chien J.W. Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Expert Rev Respir Med 2011, 5:127-135.
46. Norman B.C., Jacobsohn D.A., Williams K.M., et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011, 46:1369-1373.
47. Pidala J., Lee S.J., Quinn G., Jim H., Kim J., Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1528-1536.
48. Vogelsang G. The doorstep to the temple of wisdom. Biol Blood Marrow Transplant 2011, 17:1417-1418.
49. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: VI. Design of Clinical Trials Working Group report. Design of Clinical Trials Working Group. Biol Blood Marrow Transplant 2006, 12:491-505.
50. Vanaudenaerde B.M., Meyts I., Vos R., et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008, 32:832-843.
51. Holbro A., Lehmann T., Gambazzi F., et al. The histological pattern of lung biopsy predicts outcome of bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2011, 46:S9-S10.
52. Lorillon G., Robin M., Meignin V., et al. Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. Eur Respir J 2011, 38:470-472.
53. Lam D.C., Lam B., Wong M.K., et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT-a randomized double-blinded placebo-controlled study. Bone Marrow Transplant 2011 Feb 14, [Epub ahead of print].